{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=B%3A+Placebo&page=3", "query": { "intervention": "B: Placebo", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 2829, "total_pages": 283, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=B%3A+Placebo&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=B%3A+Placebo&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T22:37:11.499Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00614666", "title": "Safety and PK of Nikkomycin Z for Coccidioides Pneumonia Treatment", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Coccidioidomycosis" ], "interventions": [ { "name": "nikkomycin Z", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 6, "start_date": "2007-09", "completion_date": "2009-09", "has_results": true, "last_update_posted_date": "2025-04-16", "last_synced_at": "2026-10-09T22:37:11.499Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00614666" }, { "nct_id": "NCT03950882", "title": "A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Nonalcoholic Fatty Liver" ], "interventions": [ { "name": "PXL770", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Poxel SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 17, "start_date": "2019-08-01", "completion_date": "2020-03-31", "has_results": false, "last_update_posted_date": "2021-06-11", "last_synced_at": "2026-10-09T22:37:11.499Z", "location_count": 1, "location_summary": "High Point, North Carolina", "locations": [ { "city": "High Point", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03950882" }, { "nct_id": "NCT07339722", "title": "A Study of LY4515100 in Healthy Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "LY4515100 via SAD", "type": "DRUG" }, { "name": "LY4515100 via MAD", "type": "DRUG" }, { "name": "LY4515100", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Caffeine", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Iohexol", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 123, "start_date": "2026-01-15", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-09T22:37:11.499Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07339722" }, { "nct_id": "NCT07724522", "title": "Prebiotic Inulin for Late-Reproductive Individuals", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity & Overweight", "Perimenopausal Women", "Prebiotics", "Inulin", "Muscle, Skeletal", "Cardiovascular Diseases (CVD)", "Microbiota", "Gastrointestinal Microbiome", "Dietary Fiber", "Women Health", "Vascular Health", "Insulin Resistance" ], "interventions": [ { "name": "Inulin", "type": "DIETARY_SUPPLEMENT" }, { "name": "Maltodextrin (Placebo)", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "George Washington University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "40 Years to 55 Years · Female only" }, "enrollment_count": 27, "start_date": "2026-08-01", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-09T22:37:11.499Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07724522" }, { "nct_id": "NCT04828161", "title": "A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "ensovibep", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 407, "start_date": "2021-05-10", "completion_date": "2022-01-27", "has_results": true, "last_update_posted_date": "2026-01-27", "last_synced_at": "2026-10-09T22:37:11.499Z", "location_count": 27, "location_summary": "Jasper, Alabama • Colton, California • Fullerton, California + 21 more", "locations": [ { "city": "Jasper", "state": "Alabama" }, { "city": "Colton", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Redondo Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04828161" }, { "nct_id": "NCT00300469", "title": "Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Mixed Dyslipidemia", "Coronary Heart Disease", "Dyslipidemia" ], "interventions": [ { "name": "ABT-335", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 613, "start_date": "2006-03", "completion_date": null, "has_results": true, "last_update_posted_date": "2009-06-03", "last_synced_at": "2026-10-09T22:37:11.499Z", "location_count": 1, "location_summary": "North Chicago, Illinois", "locations": [ { "city": "North Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00300469" }, { "nct_id": "NCT04539041", "title": "Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Progressive Supranuclear Palsy (PSP)" ], "interventions": [ { "name": "antisense oligonucleotide", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "40 Years to 75 Years" }, "enrollment_count": 59, "start_date": "2021-02-16", "completion_date": "2024-10-17", "has_results": false, "last_update_posted_date": "2025-12-24", "last_synced_at": "2026-10-09T22:37:11.499Z", "location_count": 3, "location_summary": "La Jolla, California • Rochester, Minnesota • Nashville, Tennessee", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04539041" }, { "nct_id": "NCT02720094", "title": "Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cabotegravir Oral Tablet", "type": "DRUG" }, { "name": "TDF/FTC tablets", "type": "DRUG" }, { "name": "Placebo for TDF/FTC tablets", "type": "DRUG" }, { "name": "Placebo for cabotegravir oral tablet", "type": "DRUG" }, { "name": "CAB LA", "type": "DRUG" }, { "name": "Placebo for CAB LA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4570, "start_date": "2016-12-19", "completion_date": "2025-03-31", "has_results": true, "last_update_posted_date": "2026-03-19", "last_synced_at": "2026-10-09T22:37:11.499Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Los Angeles, California • Oakland, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02720094" }, { "nct_id": "NCT01636141", "title": "Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "OLT1177 Gel", "type": "DRUG" }, { "name": "Placebo gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Olatec Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 36, "start_date": "2012-06", "completion_date": "2012-08", "has_results": false, "last_update_posted_date": "2012-09-06", "last_synced_at": "2026-10-09T22:37:11.499Z", "location_count": 1, "location_summary": "College Station, Texas", "locations": [ { "city": "College Station", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01636141" }, { "nct_id": "NCT03334851", "title": "Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus", "Rheumatoid Arthritis" ], "interventions": [ { "name": "PF-06835375", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 74, "start_date": "2017-11-17", "completion_date": "2022-02-15", "has_results": true, "last_update_posted_date": "2023-10-30", "last_synced_at": "2026-10-09T22:37:11.499Z", "location_count": 17, "location_summary": "Anniston, Alabama • Beverly Hills, California • Los Angeles, California + 9 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Anniston", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Clearwater", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03334851" } ] }